Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.50 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 8/20 | 0.49 |
| ▸ | SRC | P12931 | 6/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CSK | P41240 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545423 | 0.95 | MAPK14 (0.49) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 | |
| SCHEMBL545648 | 0.94 | ABL1 (0.58) | ABL1SRCEGFRBRAF | |
| SCHEMBL5416351 | 0.89 | RAF1 (0.45) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 | |
| SCHEMBL545439 | 0.88 | MAPK14 (0.44) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 | |
| SCHEMBL545984 | 0.85 | ABL1 (0.55) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 | |
| SCHEMBL10199956 | 0.85 | RAF1 (0.49) | RAF1BRAFHTT | |
| SCHEMBL10199733 | 0.85 | KDR (0.42) | RAF1BRAF | |
| SCHEMBL545637 | 0.85 | KDR (0.52) | MAPK14MAP3K20MAP3K7ABL1SRC | |
| SCHEMBL14493361 | 0.84 | ABL1 (0.54) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 | |
| SCHEMBL544927 | 0.82 | ABL1 (0.53) | MAPK14MAP3K20MAP3K7MAP4K2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | MAPK14 278/4885MAP3K20 1/4885MAP3K7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.